MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
Applied Molecular Transport Total Shareholders Equity 2011-2026 | AMTI
Annual Total Shareholders Equity Applied Molecular Transport
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 60.8 M | 164 M | 132 M | -71.7 M | -44.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 164 M | -71.7 M | 48.1 M |
Quarterly Total Shareholders Equity Applied Molecular Transport
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.2 M | 20.6 M | 36.1 M | 60.8 M | 78.4 M | 97.8 M | 128 M | 164 M | 188 M | 208 M | 114 M | 132 M | 132 M | 132 M | 132 M | -71.7 M | -71.7 M | -71.7 M | -49.1 M | -44.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 208 M | -71.7 M | 66.4 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
967 M | $ 3.46 | 1.72 % | $ 1.03 B |  Canada |
 |
Altimmune
ALT
|
225 M | $ 3.47 | 3.89 % | $ 306 M |  USA |
 |
Amgen
AMGN
|
8.66 B | $ 350.07 | 0.63 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 19.49 | -0.05 % | $ 911 M | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 220.18 | -0.77 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
Aurinia Pharmaceuticals
AUPH
|
581 M | $ 14.83 | 5.78 % | $ 1.99 B | Canada |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.42 | 3.64 % | $ 362 M | Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Axsome Therapeutics
AXSM
|
88.3 M | $ 154.69 | -1.42 % | $ 7.7 B | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
6.09 B | $ 54.66 | 0.97 % | $ 10.5 B | USA |
 |
Benitec Biopharma
BNTC
|
97.3 M | $ 11.25 | 2.46 % | $ 463 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
409 M | $ 12.74 | - | $ 768 M | USA |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.59 | 4.28 % | $ 186 M | USA |
 |
Calithera Biosciences
CALA
|
8.38 M | - | -10.95 % | $ 876 K | USA |
 |
Cellectis S.A.
CLLS
|
309 M | $ 3.38 | 1.05 % | $ 116 M | France |
 |
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
103 M | $ 2.13 | 1.9 % | $ 199 M | Israel |
 |
Denali Therapeutics
DNLI
|
1.23 B | $ 20.96 | 3.89 % | $ 3.45 B | USA |
 |
Dyadic International
DYAI
|
5.88 M | $ 0.86 | -8.51 % | $ 24.8 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
CorMedix
CRMD
|
405 M | $ 6.33 | 1.28 % | $ 456 K | USA |